Affiliation:
1. 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2. 2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
3. 3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
Abstract
Abstract
Acute myeloid leukemia (AML) can be treated with either high- or low-intensity regimens. Highly sensitive assays for measurable residual disease (MRD) now allow for a more precise assessment of response quality. We hypothesized that treatment (Rx) intensity may not be a key predictor of outcomes, assuming that an optimal response to therapy is achieved. We performed a single-center retrospective study including 635 patients with newly diagnosed AML responding to either intensive cytarabine/anthracycline-based chemotherapy (IA; n = 385) or low-intensity venetoclax-based regimens (LOW + VEN; n = 250) and who had adequate flow cytometry–based MRD testing performed at the time of best response. The median overall survival (OS) was 50.2, 18.2, 13.6, and 8.1 months for the IA MRD−, LOW + VEN MRD−, IA MRD+, and LOW + VEN MRD+ cohorts, respectively. The 2-year cumulative incidence of relapse (CIR) was 41.1%, 33.5%, 64.2%, and 59.9% for the IA MRD−, LOW + VEN MRD−, IA MRD+, and LOW + VEN MRD+ cohorts, respectively. The CIR was similar between patients within MRD categories irrespective of the treatment regimen received. The IA cohort was enriched for younger patients and favorable AML cytogenetic/molecular categories. Using multivariate analysis, age, best response (complete remission [CR]/CR with incomplete hematologic recovery/morphologic leukemia-free state), MRD status, and European LeukemiaNet (ELN) 2017 risk remained significantly associated with OS, whereas best response, MRD status, and ELN 2017 risk were significantly associated with CIR. Treatment intensity was not significantly associated with either OS or CIR. Achievement of MRD− CR should be the key objective of AML therapy in both high- and low-intensity treatment regimens.
Publisher
American Society of Hematology
Reference39 articles.
1. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia;Yates;Cancer Chemother Rep,1973
2. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome;Estey;Blood,1999
3. Cladribine combined with idarubicin and Ara-C (CLIA) as a frontline and salvage treatment for young patients (≤65 yrs) with acute myeloid leukemia;Jain;Blood,2016
4. Howlader
N
, NooneA, KrapchoM, . SEER cancer statistics review, 1975-2018. National Cancer Institute, Bethesda, MD. Accessed 18 August 2022. https://seer.cancer.gov/csr/1975_2018/.
5. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes;Cheson;J Clin Oncol,1986
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献